Sirolimus suppresses circulating fibrocytes in idiopathic pulmonary fibrosis in a randomized controlled crossover trial

Sirolimus suppresses circulating fibrocytes in idiopathic pulmonary fibrosis in a randomized controlled crossover trial

BACKGROUND Fibrocytes are BM-derived circulating cells that traffic to the injured lungs and contribute to fibrogenesis. The mTOR inhibitor, sirolimus, inhibits fibrocyte CXCR4 expression, reducing fibrocyte traffic and attenuating lung fibrosis in animal models. We sought to test the hypothesis tha...

Full description

Bibliographic Details
Main Authors: Diana C. Gomez-Manjarres, Dierdre B. Axell-House, Divya C. Patel, John Odackal, Victor Yu, Marie D. Burdick, Borna Mehrad
Format: Article
Language:English
Published: American Society for Clinical investigation 2023-04-01
Series:JCI Insight
Subjects:
Pulmonology
Online Access:https://doi.org/10.1172/jci.insight.166901

Similar Items

Similar Items